Skip to main content
Top
Published in: American Journal of Clinical Dermatology 4/2003

01-04-2003 | Current Opinion

Patients’ Vehicle Preference for Corticosteroid Treatments of Scalp Psoriasis

Authors: Dr Steven R. Feldman, Tamara S. Housman

Published in: American Journal of Clinical Dermatology | Issue 4/2003

Login to get access

Abstract

Topical therapy is one of the foundations of dermatology. The vehicles used to deliver topical therapy have considerable impact on efficacy. The vehicle can have direct effects on disease; it can impact the delivery of the active drug, and its characteristics affect patient compliance. While the physical chemistry of vehicles has been studied in great detail, there has been very little study of patients’ preferences for different vehicles and even less on the effect of these preferences on patient compliance. Such study is essential, as noncompliance with topical therapy is very common, and likely impacts the response to topical therapy observed in clinical practice. This manuscript discusses information on patients’ preferences for different vehicles, focussing on the treatment of scalp psoriasis. Significant vehicle characteristics such as ease or difficulty of use, messiness, odors, and staining are recognized to affect patients’ preferences. An instrument based on these characteristics has been used to compare patients’ preferences for different vehicles. Patients with psoriasis generally prefer less messy vehicles, such as foam and solution preparations, to traditional cream and ointment vehicles. These preferences have the potential to impact patient compliance. Studies directly measuring patient compliance have not yet been performed. In conclusion, the choice of vehicles impacts both the potency of the medication and patients’ acceptance of the treatment. Actual effects of different vehicles on compliance are important but have not yet been adequately studied.
Footnotes
1
Use of tradenames is for product identification only and does not imply endorsement.
 
Literature
2.
3.
go back to reference McMichael A, Feldman SR. How to treat common scalp dermatoses. Skin Aging 1999; 7: 44–52 McMichael A, Feldman SR. How to treat common scalp dermatoses. Skin Aging 1999; 7: 44–52
4.
go back to reference Franz TJ, Parsell DA, Myers JA, et al. Clobetasol propionate foam 0.05 %: a novel vehicle with enhanced delivery. Int J Dermatol 2000; 39: 521–538CrossRef Franz TJ, Parsell DA, Myers JA, et al. Clobetasol propionate foam 0.05 %: a novel vehicle with enhanced delivery. Int J Dermatol 2000; 39: 521–538CrossRef
5.
go back to reference Olsen EA, Cram DL, Ellis CN, et al. A double-blind, vehicle-controlled study of clobetasol propionate 0.0 5% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol 1991; 24: 443–447PubMedCrossRef Olsen EA, Cram DL, Ellis CN, et al. A double-blind, vehicle-controlled study of clobetasol propionate 0.0 5% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol 1991; 24: 443–447PubMedCrossRef
6.
go back to reference Katz HI, Lindholm JS, Weiss JS, et al. Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis. Clin Ther 1995; 17: 390–401PubMedCrossRef Katz HI, Lindholm JS, Weiss JS, et al. Efficacy and safety of twice-daily augmented betamethasone dipropionate lotion versus clobetasol propionate solution in patients with moderate-to-severe scalp psoriasis. Clin Ther 1995; 17: 390–401PubMedCrossRef
7.
go back to reference Rapp SR, Exum ML, Reboussin DM, et al. The physical, psychological and social impact of psoriasis. J Health Psychol 1997; 2: 525–537PubMedCrossRef Rapp SR, Exum ML, Reboussin DM, et al. The physical, psychological and social impact of psoriasis. J Health Psychol 1997; 2: 525–537PubMedCrossRef
8.
go back to reference Rapp SR, Feldman SR, Fleischer Jr AB, et al. Health related quality of life in psoriasis: a biopsychosocial model and measures. In: Rajagopalan R, Sherertz EF, Anderson R. Care management of skin diseases: life quality and economic impact. New York: Marcel Dekker Inc, 1998: 125-45 Rapp SR, Feldman SR, Fleischer Jr AB, et al. Health related quality of life in psoriasis: a biopsychosocial model and measures. In: Rajagopalan R, Sherertz EF, Anderson R. Care management of skin diseases: life quality and economic impact. New York: Marcel Dekker Inc, 1998: 125-45
9.
go back to reference Housman TS, Mellen B, Rapp SR, et al. Psoriasis patients prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis 2002; 70 (6): 327–332PubMed Housman TS, Mellen B, Rapp SR, et al. Psoriasis patients prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis 2002; 70 (6): 327–332PubMed
10.
go back to reference Richards HL, Fortune DG, O’Sullivan TM, et al. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999; 41: 581–583PubMed Richards HL, Fortune DG, O’Sullivan TM, et al. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999; 41: 581–583PubMed
11.
go back to reference Balkrishnan R, Carroll CL, Camacho FT, et al. Electronic monitoring of medication adherence in skin disease: results of a pilot study in psoriasis. J Am Acad Dermatol. In press Balkrishnan R, Carroll CL, Camacho FT, et al. Electronic monitoring of medication adherence in skin disease: results of a pilot study in psoriasis. J Am Acad Dermatol. In press
12.
go back to reference Herz G, Blum G, Yawalkar S. Halobetasol propionate cream by day and halobetasol propionate ointment at night for the treatment of pediatric patients with chronic, localized plaque psoriasis and atopic dermatitis. J Am Acad Dermatol 1991 Dec; 25 (6 Pt 2): 1166–1169CrossRef Herz G, Blum G, Yawalkar S. Halobetasol propionate cream by day and halobetasol propionate ointment at night for the treatment of pediatric patients with chronic, localized plaque psoriasis and atopic dermatitis. J Am Acad Dermatol 1991 Dec; 25 (6 Pt 2): 1166–1169CrossRef
13.
go back to reference George YA, Ravis SM, Gottlieb J, et al. Betamethasone Valerate 0.12 % in Foam Vehicle for Scalp Seborrheic Dermatitis in African Americans. Cosmet Dermatol 2002; 15 (7): 23–27 George YA, Ravis SM, Gottlieb J, et al. Betamethasone Valerate 0.12 % in Foam Vehicle for Scalp Seborrheic Dermatitis in African Americans. Cosmet Dermatol 2002; 15 (7): 23–27
14.
go back to reference Housman TS, McMichael AJ, Mellen BG, et al. Use of 0.12 % betamethasone valerate foam vs 0.0 1% fluocinolone acetonide topical oil to treat scalp psoriasis: quantitative assessment of patient preference and treatment efficacy. Cosmet Dermatol 2002; 15 (11): 27–30 Housman TS, McMichael AJ, Mellen BG, et al. Use of 0.12 % betamethasone valerate foam vs 0.0 1% fluocinolone acetonide topical oil to treat scalp psoriasis: quantitative assessment of patient preference and treatment efficacy. Cosmet Dermatol 2002; 15 (11): 27–30
15.
go back to reference Bikowski J. The use of therapeutic moisturizers in various dermatologic disorders. Cutis 2001; 68 (5 Suppl.): 3–11PubMed Bikowski J. The use of therapeutic moisturizers in various dermatologic disorders. Cutis 2001; 68 (5 Suppl.): 3–11PubMed
16.
go back to reference Stein LF, Sherr A, Solodkina G, et al. Betamethasone valerate foam for treatment of nonscalp psoriasis. J Cutan Med Surg 2001; 5: 303–307PubMedCrossRef Stein LF, Sherr A, Solodkina G, et al. Betamethasone valerate foam for treatment of nonscalp psoriasis. J Cutan Med Surg 2001; 5: 303–307PubMedCrossRef
17.
go back to reference Feldman SR, Ravis SM, Fleischer Jr AB, et al. Betamethasone valerate in foam vehicle is effective with both daily and twice a day dosing: a single-blind, open-label study in the treatment of scalp psoriasis. J Cutan Med Surg 2001; 5: 386–389PubMedCrossRef Feldman SR, Ravis SM, Fleischer Jr AB, et al. Betamethasone valerate in foam vehicle is effective with both daily and twice a day dosing: a single-blind, open-label study in the treatment of scalp psoriasis. J Cutan Med Surg 2001; 5: 386–389PubMedCrossRef
Metadata
Title
Patients’ Vehicle Preference for Corticosteroid Treatments of Scalp Psoriasis
Authors
Dr Steven R. Feldman
Tamara S. Housman
Publication date
01-04-2003
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 4/2003
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200304040-00001

Other articles of this Issue 4/2003

American Journal of Clinical Dermatology 4/2003 Go to the issue

Adis Drug Profile

Alefacept

Adis Drug Profile

Alefacept